These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31096805)

  • 21. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
    Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
    Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective effect of sodium stearate on the moisture-induced deterioration of hygroscopic spray-dried powders.
    Yu J; Romeo MC; Cavallaro AA; Chan HK
    Int J Pharm; 2018 Apr; 541(1-2):11-18. PubMed ID: 29454904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
    Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
    Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
    Yu H; Teo J; Chew JW; Hadinoto K
    Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
    Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D
    Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations.
    Guchardi R; Frei M; John E; Kaerger JS
    Int J Pharm; 2008 Feb; 348(1-2):10-7. PubMed ID: 17689898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
    Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
    Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.
    Wilson EM; Luft JC; DeSimone JM
    Pharm Res; 2018 Aug; 35(10):195. PubMed ID: 30141117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical stability of dry powder inhaler formulations.
    Shetty N; Cipolla D; Park H; Zhou QT
    Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
    [No Abstract]   [Full Text] [Related]  

  • 32. From single excipients to dual excipient platforms in dry powder inhaler products.
    Shur J; Price R; Lewis D; Young PM; Woollam G; Singh D; Edge S
    Int J Pharm; 2016 Dec; 514(2):374-383. PubMed ID: 27262269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
    Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis.
    Zhang Y; MacKenzie B; Koleng JJ; Maier E; Warnken ZN; Williams RO
    Mol Pharm; 2020 Feb; 17(2):632-644. PubMed ID: 31913640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.